TEST DIRECTORY

0 selected

Laboratory：Hachioji

○viral hepatitis

TEST NAME

 SPECIMEN
REQUIREMENT
（ｍL）		 CONTAINER CAP COLOR STORE
TEMPERATURE
(STABILITY)		 TURNAROUND
TIME (DAY)		 METHODOLOGY REFERENCE RANGE
(UNIT)

HBV genotype

serum
0.6
S09
↓
A00 		Refrigeration
 2-4 EIA

Enzyme immunoassay (EIA)
EIA is based on the same assay principle as RIA. Using either enzyme-labeled antigen or antibody as a labeledsubstance, the antigen-antibody reaction is carried out. After adding a chromogenic substrate, the enzyme activity is measured.

HBV DNA quantitative, IU

serum
1.8
S5F Freeze
（21 days）
 3-5 PCR(Real-time PCR)

Real-time PCR
Real-time PCR is the one of the nucleic acid amplification tests using polymerase chain reaction (PCR) as the basic principle. By the use of oligonucleotide that yields fluorescence after degradation, the fluorescent signal is identified for each PCR cycle, which enables the real-time quantification of the target nucleic acid.

 None-detected
(Log IU/mL)

HBs antigen (HQ)

serum
0.6
S09
↓
A00 		Freeze
（21 days）
 2-4 CLEIA

Chemiluminescent enzyme immunoassay (CLEIA)
Antibodies linked to the solid phase are reacted with antigens that are secondarily reacted with enzyme-labeled antibodies.
After adding a chemiluminescent substrate, the emission intensity is measured.

 < 0.005
(IU/mL)

HBs antibody, CLEIA

serum
0.5
S09
↓
A00 		Refrigeration
 2-4 CLEIA

Chemiluminescent enzyme immunoassay (CLEIA)
Antibodies linked to the solid phase are reacted with antigens that are secondarily reacted with enzyme-labeled antibodies.
After adding a chemiluminescent substrate, the emission intensity is measured.

 < 10.0
(mIU/mL)

HBs antibody

serum
0.2
S09
↓
A00 		Refrigeration
 2-4 Passive hemagglutination(PHA)

Passive hemagglutination (PHA)
The surface of red blood cells is coated with antigen to form sensitized red blood cells. Using the sensitized red blood cells, the antigen-antibody reaction is carried
out. The presence of the antibody is determined based on appearance or non-appearance of clots.

 < 8
(x)

Hepatitis B virus core antigen (HBcrAg)

serum
0.5
S09
↓
A00 		Refrigeration
 2-5 CLEIA

Chemiluminescent enzyme immunoassay (CLEIA)
Antibodies linked to the solid phase are reacted with antigens that are secondarily reacted with enzyme-labeled antibodies.
After adding a chemiluminescent substrate, the emission intensity is measured.

 2.1未満(LogU/mL)

HBc antibody (IgG)

serum
0.3
S09
↓
A00 		Refrigeration
 2-4 CLEIA

Chemiluminescent enzyme immunoassay (CLEIA)
Antibodies linked to the solid phase are reacted with antigens that are secondarily reacted with enzyme-labeled antibodies.
After adding a chemiluminescent substrate, the emission intensity is measured.

 C.O.I. < 1.0

IgM-HBc antibody

serum
0.5
S09
↓
A00 		Refrigeration
 2-4 CLIA

Chemiluminescent immunoassay (CLIA)
Antibodies linked to the solid phase are reacted with antigens that are secondarily reacted with chemiluminescentlabeled antibodies. The emission intensity of chemiluminescent substance is measured.

 Sample/Cutoff
(S/CO) < 1.00

HBc antibody

serum
0.3
S09
↓
A00 		Refrigeration
 2-4 Passive hemagglutination(PHA)

Passive hemagglutination (PHA)
The surface of red blood cells is coated with antigen to form sensitized red blood cells. Using the sensitized red blood cells, the antigen-antibody reaction is carried
out. The presence of the antibody is determined based on appearance or non-appearance of clots.

 Negative (< 64)
(x)

HBe antigen

serum
0.5
S09
↓
A00 		Refrigeration
 2-4 CLEIA

Chemiluminescent enzyme immunoassay (CLEIA)
Antibodies linked to the solid phase are reacted with antigens that are secondarily reacted with enzyme-labeled antibodies.
After adding a chemiluminescent substrate, the emission intensity is measured.

 C.O.I. < 1.0

HBe antibody

serum
0.7
S09
↓
A00 		Refrigeration
 2-4 CLEIA

Chemiluminescent enzyme immunoassay (CLEIA)
Antibodies linked to the solid phase are reacted with antigens that are secondarily reacted with enzyme-labeled antibodies.
After adding a chemiluminescent substrate, the emission intensity is measured.

 INHIBITION < 60
(%)

HA antibody

serum
0.4
S09
↓
A00 		Refrigeration
 2-4 CLIA

Chemiluminescent immunoassay (CLIA)
Antibodies linked to the solid phase are reacted with antigens that are secondarily reacted with chemiluminescentlabeled antibodies. The emission intensity of chemiluminescent substance is measured.

 See below.

IgM-HA antibody

serum
0.4
S09
↓
A00 		Refrigeration
 2-4 CLIA

Chemiluminescent immunoassay (CLIA)
Antibodies linked to the solid phase are reacted with antigens that are secondarily reacted with chemiluminescentlabeled antibodies. The emission intensity of chemiluminescent substance is measured.

 See below.

HCV antibody, the third generation for screening

serum
0.7
S09
↓
A00 		Refrigeration
 2-4 CLEIA

Chemiluminescent enzyme immunoassay (CLEIA)
Antibodies linked to the solid phase are reacted with antigens that are secondarily reacted with enzyme-labeled antibodies.
After adding a chemiluminescent substrate, the emission intensity is measured.

 < 1.0(-)
(COI)

HCV Grouping for interferon therapy

serum
0.5
S09
↓
A00 		Refrigeration
 2-4 CLEIA

Chemiluminescent enzyme immunoassay (CLEIA)
Antibodies linked to the solid phase are reacted with antigens that are secondarily reacted with enzyme-labeled antibodies.
After adding a chemiluminescent substrate, the emission intensity is measured.

 (Group)

HCV RNA core genotype

serum
0.5
S3F,S5F Freeze
（3 months）
 3-5 RT-PCR

Reverse transcriptase-polymerase chain reaction (RT-PCR)
When RNA to be amplified by PCR, complementary DNA (cDNA) is synthesized using reverse transcriptase (RT) using RNA as a template.

 None-detected

HCV RNA 1b (NS5A)

serum
0.5
S3F,S5F Freeze
（3 months）
 10-14 Sanger method AA2209-2248:
None-detected
(number of
variants)

HCV RNA quantitative

serum
1.8
S5F Freeze
（21 days）
 3-5 RT-PCR(Real-time PCR)

Real-time PCR
Real-time PCR is the one of the nucleic acid amplification tests using polymerase chain reaction (PCR) as the basic principle. By the use of oligonucleotide that yields fluorescence after degradation, the fluorescent signal is identified for each PCR cycle, which enables the real-time quantification of the target nucleic acid.

 None-detected(Log IU/mL)

Hepatitis C virus core antigen

serum
0.8
S09
↓
A00 		Refrigeration
 2-4 CLIA

Chemiluminescent immunoassay (CLIA)
Antibodies linked to the solid phase are reacted with antigens that are secondarily reacted with chemiluminescentlabeled antibodies. The emission intensity of chemiluminescent substance is measured.

 < 3.0
(The lower
limit of
quantification)
(fmol/L)

HCV DCVresistant mutation (L31/Y93)

serum
0.5
S3F,S5F Freeze
（21 days）
 10-14 Direct sequencing method +Cycleave PCR

HCV NS3 drug resistant mutation (D168)

serum
0.5
S3F,S5F Freeze
（21 days）
 10-14 Direct sequencing method

Direct sequencing method
Direct sequence analysis using PCR-amplified DNA as a sequencing template.

HCV NS5B-S282 mutation

serum
0.5
S3F,S5F Freeze
（21 days）
 Please contact us in advance. Direct sequencing method

Direct sequencing method
Direct sequence analysis using PCR-amplified DNA as a sequencing template.

IgA anti-HEV, qualitative

serum
0.3
S09
↓
A00 		Refrigeration
 2-5 EIA

Enzyme immunoassay (EIA)
EIA is based on the same assay principle as RIA. Using either enzyme-labeled antigen or antibody as a labeledsubstance, the antigen-antibody reaction is carried out. After adding a chromogenic substrate, the enzyme activity is measured.

 Negative

INACTIVE
HBV DNA lamivudineresistant gene（Suspended beyond orders placed 06-24-2019）

serum
0.5
S3F,S5F Freeze
（21 days）
 4-10 PCR-ELMA

INACTIVE
HBs antigen（Suspended beyond orders placed 03-31-2021）

serum
0.2
S09
↓
A00 		Refrigeration
 2-4 Magnetic agglutination test (MAT) Negative (< 8)
(x)

Notifications of URL changes/lab information added

ラボを選択してください

Choose a laboratory

Notifications of URL changes/lab information added

Laboratory List

Advanced search